文献速递胸部肿瘤放疗放疗物理与技术

放疗剂量计算算法转换中剂量学偏移的剂量学与放射生物学管理方法

Dosimetrical and radiobiological approach to manage the dosimetric shift in the transition of dose calculation algorithm in radiation oncology: how to improve high quality treatment and avoid unexpected outcomes?
PubMed 文献 · Radiat Oncol · 2018-04-03

该文提出一套分析流程,用于评估参考算法与新算法之间的剂量学改变及潜在临床变化,包括剂量学参数、伽马指数、基于等效均匀剂量概念的放射生物学指标及Bootstrap模拟统计。结果显示,计算方法对肺癌患者剂量分布和临床结局有显著影响,可能超过5-10%;使用更先进剂量计算方法时,MU显著增加(>2%)。作者建议物理师和肿瘤科医生应评估算法转换引起的剂量学偏移及其对肿瘤控制和正常组织毒性的影响。

要点

  • 剂量计算算法转换可引起剂量学偏移,需物理师和肿瘤科医生共同评估。
  • 肺癌患者中计算方法对剂量分布和临床结局的影响可能超过5-10%。
  • 先进算法较参考算法所需MU显著增加(>2%)。

核心结论

  • 剂量计算算法的改变可能引起剂量学偏移,必须由物理师和肿瘤科医生评估其对肿瘤控制和正常组织毒性的影响。

研究设计与样本

  • 本文提出一套通用分析流程,用于评估参考算法与新算法之间的剂量学改变和潜在临床变化。
  • 分析流程包括剂量学参数、伽马指数、基于等效均匀剂量概念的放射生物学指标以及Bootstrap模拟统计。

主要发现

  • 剂量学和放射生物学数据显示,计算方法对肺癌患者的剂量分布和临床结局有显著影响,可能超过5-10%。
  • Wilcoxon符号秩配对比较表明,与参考算法相比,使用更先进剂量计算方法时所需MU显著增加(>2%)。

关键数值与推荐

  • 先进剂量计算方法较参考算法所需MU显著增加(>2%)。
  • 计算方法对肺癌患者剂量分布和临床结局的影响可能超过5-10%。

临床怎么用

  • 在新算法临床使用前,应通过剂量学、放射生物学和统计测试评估剂量学偏移。
  • 剂量处方或危及器官剂量限值的使用需结合算法转换后的剂量学偏移进行考量。

局限性

  • 本文未报告研究样本量、具体P值及置信区间等统计细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: For a given prescribed dose of radiotherapy, with the successive generations of dose calculation algorithms, more monitor units (MUs) are generally needed. This is due to the implementation of successive improvements in dose calculation: better heterogeneity correction and more accurate estimation of secondary electron transport contribution. More recently, there is the possibility to report the dose-to-medium, physically more accurate compared to the dose-to-water as the reference one. This last point is a recent concern and the main focus of this study. METHODS: In this paper, we propose steps for a general analysis procedure to estimate the dosimetric alterations, and the potential clinical changes, between a reference algorithm and a new one. This includes dosimetric parameters, gamma index, radiobiology indices based on equivalent uniform dose concept and statistics with bootstrap simulation. Finally, we provide a general recommendation on the clinical use of new algorithms regarding the dose prescription or dose limits to the organs at risks. RESULTS: The dosimetrical and radiobiological data showed a significant effect, which might exceed 5-10%, of the calculation method on the dose the distribution and clinical outcomes for lung cancer patients. Wilcoxon signed rank paired comparisons indicated that the delivered dose in MUs was significantly increased (> 2%) using more advanced dose calculation methods as compared to the reference one. CONCLUSION: This paper illustrates and explains the use of dosimetrical, radiobiologcal and statistical tests for dosimetric comparisons in radiotherapy. The change of dose calculation algorithm may induce a dosimetric shift, which has to be evaluated by the physicists and the oncologists. This includes the impact on tumor control and on the risk of toxicity based on normal tissue dose constraints. In fact, the alteration in dose distribution makes it hard to keep exactly the same tumor control probability along with the same normal tissue complication probability.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Chaikh A, Ojala J, Khamphan C, et al. Dosimetrical and radiobiological approach to manage the dosimetric shift in the transition of dose calculation algorithm in radiation oncology: how to improve high quality treatment and avoid unexpected outcomes? Radiat Oncol. 2018. PMID: 29615079. doi:10.1186/s13014-018-1005-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。